Celgene Co. (NASDAQ:CELG) Holdings Lifted by Perella Weinberg Partners Capital Management LP

Perella Weinberg Partners Capital Management LP grew its position in Celgene Co. (NASDAQ:CELG) by 26.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 373,965 shares of the biopharmaceutical company’s stock after purchasing an additional 77,278 shares during the period. Celgene makes up approximately 1.5% of Perella Weinberg Partners Capital Management LP’s holdings, making the stock its 13th biggest position. Perella Weinberg Partners Capital Management LP’s holdings in Celgene were worth $34,569,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Celgene by 89.3% in the first quarter. FMR LLC now owns 16,656,629 shares of the biopharmaceutical company’s stock valued at $1,571,387,000 after acquiring an additional 7,856,422 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Celgene by 8.6% in the fourth quarter. Geode Capital Management LLC now owns 9,942,267 shares of the biopharmaceutical company’s stock valued at $636,179,000 after acquiring an additional 787,638 shares in the last quarter. Abrams Capital Management L.P. bought a new position in shares of Celgene in the first quarter valued at approximately $637,066,000. American Century Companies Inc. boosted its holdings in shares of Celgene by 4.7% in the first quarter. American Century Companies Inc. now owns 3,865,722 shares of the biopharmaceutical company’s stock valued at $364,692,000 after acquiring an additional 172,466 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Celgene by 1.0% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,990,147 shares of the biopharmaceutical company’s stock valued at $282,090,000 after acquiring an additional 28,374 shares in the last quarter. Hedge funds and other institutional investors own 74.84% of the company’s stock.

Several research firms have recently issued reports on CELG. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday. BidaskClub cut shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 24th. Cantor Fitzgerald cut shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price objective for the company. in a report on Friday, April 5th. Cowen reiterated a “hold” rating and issued a $102.00 price objective on shares of Celgene in a report on Tuesday. Finally, Mizuho reiterated a “buy” rating and issued a $103.00 price objective on shares of Celgene in a report on Wednesday, July 3rd. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have given a buy rating to the company. Celgene currently has an average rating of “Hold” and a consensus target price of $94.81.

CELG stock traded up $0.20 on Friday, hitting $93.25. 215,100 shares of the company’s stock traded hands, compared to its average volume of 3,409,953. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $98.97. The firm has a market cap of $65.31 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 0.44 and a beta of 1.45. The stock’s fifty day moving average is $93.46. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78.

Celgene (NASDAQ:CELG) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, beating the consensus estimate of $2.44 by $0.17. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The business had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.22 billion. During the same period in the prior year, the business earned $2.16 earnings per share. The business’s quarterly revenue was up 15.4% on a year-over-year basis. On average, equities analysts expect that Celgene Co. will post 9.85 EPS for the current year.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.